How Did Anagenics Limited (ASX:AN1) Reduce Cash Outflows While Reporting New Royalty Invoices?

Aditi Sarkar

29 October 2026 05:09 PM AEDT

How Did Anagenics Limited (ASX:AN1) Reduce Cash Outflows While Reporting New Royalty Invoices?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

On 29 October 2026, Anagenics Limited (ASX:AN1) was quoted at AUD 0.005, with the daily change shown as unchanged. This article covers operating cash movement, ysb royalty invoicing and receipts and the company’s wider disclosures.
Anagenics reduced first-quarter FY27 operating cash outflows to AUD 10,000 from approximately AUD 300,000 a year earlier.
The company reported YSB royalty receipts and a further invoice for the September quarter.

Anagenics Limited (ASX:AN1) has reported financial and commercial developments relevant to its FY26 and FY27 activities. On 29 October 2026, Anagenics Limited (ASX:AN1) was quoted at AUD 0.005, with the daily change shown as unchanged. Anagenics reduced first-quarter FY27 operating cash outflows to AUD 10,000 from approximately AUD 300,000 a year earlier. The company reported YSB royalty receipts and a further invoice for the September quarter. The disclosures also address quarterly operating costs and next quarter position.

Operating Cash Movement

Anagenics reported net operating cash outflow of AUD 10,000 for the September 2026 quarter, against approximately AUD 300,000 in the corresponding FY26 quarter. The company attributed the difference to restructuring of its business operations and stated that it was trading profitably at the time of its update. The statement about profitability was management’s description of current operations and was not presented as a statutory quarterly net profit figure. Its Appendix 4C recorded AUD 1.381 million in customer receipts during the reporting period.

YSB Royalty Invoicing and Receipts

During Q1 FY27, Anagenics received AUD 446,000 in YSB product-line royalty revenue that had been invoiced in the June 2026 quarter. It separately invoiced AUD 377,000 in royalties relating to the three months ended 30 September 2026, with collection reported in October. These two amounts relate to different billing periods and should not be combined as identical September-quarter earned revenue. The update reflected the timing difference between invoice recognition and cash receipt across quarter ends.

Quarterly Operating Costs

The quarterly cash flow report recorded AUD 756,000 of payments for product manufacturing and operating costs, AUD 42,000 for advertising and marketing, AUD 242,000 in staff and director costs and AUD 351,000 in administrative and corporate costs. Directors’ fees were AUD 31,000 for the period. The company reported AUD 33,000 of repayments associated with borrowings and leasing. The categories are cash-flow items in the Appendix 4C rather than an audited income statement of expenses.

Business Operations and Distribution

Anagenics operates in health, beauty and wellness, including proprietary and licensed brands. Its subsidiary BLC Cosmetics distributes Australian and international cosmetic and wellness products. In the September update, management linked recent operating changes with the reduction in net cash used in operations. The company also indicated that it was looking for opportunities consistent with its strategy and business objectives. It did not identify a completed acquisition or a new specific transaction in that short activity report.

Next Quarter Position

The company said it expected to generate operating cash flow going forward following restructuring. That expectation remains prospective and separate from the reported AUD 10,000 operating cash outflow in Q1 FY27. Its YSB royalty receipts, fresh invoicing and operating cash statement were the principal financial details disclosed. The company’s announcement did not include a complete audited revenue and profit statement for the quarter, so the disclosed customer receipts and royalties should not be presented as full statutory earnings figures.

Key Insights

Overall, Anagenics Limited reported anagenics reduced first-quarter FY27 operating cash outflows to AUD 10,000 from approximately AUD 300,000 a year earlier. the company reported YSB royalty receipts and a further invoice for the September quarter. The announcement also addresses quarterly operating costs, business operations and distribution and next quarter position. These are company-reported results and planned activities for their stated periods; announced targets, proposed transactions and pending approvals remain distinct from completed outcomes.

FAQs

Q: What was Anagenics’ Q1 FY27 operating cash outflow?

A: AUD 10,000.

Q: What was the prior-year quarterly outflow?

A: Approximately AUD 300,000.

Q: How much YSB royalty cash was received?

A: AUD 446,000 from a previously issued invoice.

Q: What September-quarter royalty amount was invoiced?

A: AUD 377,000.

Q: What were total customer receipts?

A: AUD 1.381 million in the quarterly cash flow report.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.